Colon cancer is a top lethal cancer for men and women worldwide (Selvam et al., 2019; Lichtenstern et al., 2020) and K-Ras mutation is one of the most frequently activated oncogenes observed in around 40% of colorectal carcinomas (Morkel et al., 2015). This evidence concerns the gene KRAS and colonic neoplasm.